"Next-Gen Endovascular Robotics"
Houston, Texas endovascular robotics company founded 2017 as a UTHealth spin-out; makes the Iris intracranial robotic navigation system for aneurysms.
XCath is a medical robotics company founded in 2017 as a spin-out from UTHealth's Microsurgical Robotics Laboratory, headquartered in Houston, Texas, with an additional office in Pangyo, South Korea. Fred Moll, co-founder of Intuitive Surgical, chairs the company's board, and Eduardo Fonseca serves as chief executive.
The company's Iris Surgical Robotic System is an endovascular robot built for intracranial navigation, using steerable guidewire and catheter technology to reach cerebrovascular sites for the treatment of brain aneurysms and stroke. In November 2025, Dr. Vitor Mendes Pereira used the Iris system to perform the first-in-human robotic-assisted treatment of a complex brain aneurysm at the Panama Clinic, and the system subsequently completed what the company describes as the first telerobotic mechanical thrombectomy for stroke.
XCath has raised more than $92 million in total funding, including a $30 million Series C round announced in March 2026, and is advancing the Iris platform toward broader use in neurointerventional care.
Primary type & automation activities this supplier delivers:
Endovascular robotic system for minimally invasive neurovascular treatment including brain aneurysms
Contact XCath
WEBSITE
https://xcath.comHEADQUARTERS
United States
Company Facts
Founded
2017
Primary Role
Manufacturer
Company Size
-
Primary Region
North America
Annual Sales
-
Funding Stage
-
Funding Total
-